WO2000021470A1 - Composites for tissue regeneration and methods of manufacture thereof - Google Patents
Composites for tissue regeneration and methods of manufacture thereof Download PDFInfo
- Publication number
- WO2000021470A1 WO2000021470A1 PCT/US1999/023732 US9923732W WO0021470A1 WO 2000021470 A1 WO2000021470 A1 WO 2000021470A1 US 9923732 W US9923732 W US 9923732W WO 0021470 A1 WO0021470 A1 WO 0021470A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- region
- bone
- devices
- powder
- materials
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/165—Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
- B33Y70/10—Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/468—Testing instruments for artificial joints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30011—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30301—Three-dimensional shapes saddle-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30762—Means for culturing cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30766—Scaffolds for cartilage ingrowth and regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/3093—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth for promoting ingrowth of bone tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30952—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using CAD-CAM techniques or NC-techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30962—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using stereolithography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30968—Sintering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/3097—Designing or manufacturing processes using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30971—Laminates, i.e. layered products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4644—Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material
- A61F2002/4648—Means for culturing bone graft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0095—Saddle-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00185—Ceramics or ceramic-like structures based on metal oxides
- A61F2310/00203—Ceramics or ceramic-like structures based on metal oxides containing alumina or aluminium oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/7532—Artificial members, protheses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
Definitions
- the invention relates generally to implantable devices characterized by gradients of materials, architecture, and/or properties for tissue regeneration, made using solid free-form fabrication technology, which can be combined with computer-aided design.
- Bone deficit or defects may result from congenital defects, disease, aging, or trauma. Bones are composed of highly vascularized tissue, called osseous tissue, which harbors blood-forming elements, the marrow. The external and internal structure of bone is in dynamic flux: the cellular elements produce and remodel a matrix of cartilage in which calcium salts are deposited. Approximately two-thirds of mature bone is calcium phosphate as hydroxyapatite, one third is predominantly collagen fibers and other calcium salts, while only 2% by weight is living cells. Through processes of calcium resorption and deposition, osteocytes and various other cell types are able to remodel or heal bone as needed while the skeleton continues to provide structural support for the body.
- Bone is further divided into dense (compact) and spongy (cancellous) areas. Because it has the greater mechanical strength, compact bone is positioned to receive the greatest physical loads generated by the weight of the body and skeletal muscle contractions.
- Compact bone forms along the surface of the long axis of the long bones forming what is known as the cortex of the bone.
- Spongy bone composes the "head" (epiphysis) and the inner areas of the bones, and borders the medullary cavity in the larger bones.
- Cartilage on the other hand, is an avascular tissue composed of 5- 10% by weight of living cells.
- Hyaline cartilage covers the epiphyses of the bone and, in syno vial joints, lies within a fluid filled
- Fibrocartilage composes the intervertebral discs separating the vertebrae of the spinal columns. Elastic cartilage is present in areas requiring extreme resilience, such as the tip of the nose. Cartilage is formed by and contains cells called chondrocytes.
- the extracellular matrix of hyaline cartilage contains closely packed Type II collagen fibers and proteoglycans including hyaluronate and glycoaminoglycans in a chondroitin sulfate matrix.
- Chondrocytes receive nutrients and dispose of wastes by diffusion through the matrix and are believed to have limited mobility or ability to divide and regenerate damaged tissue. Chondrocytes normally produce anti- angiogenesis factors.
- grafts of living tissue have recently moved from direct implantation of freshly harvested fully formed tissue, e.g. skin grafts or organ transplants, to strategies involving seeding of cells on matrices which will regenerate or encourage the regeneration of local structures.
- tissue e.g. skin grafts or organ transplants
- the device must serve as a scaffold of specific architecture which will encourage the migration, residence and proliferation of specific cell types as
- the overall porosity of the device is important. Additionally, the individual pore diameter or size is an important factor in determining the ability of cells to migrate into, colonize, and differentiate while in the device (Martin, RB et al. Biomaterials, 14: 341, 1993). For skeletal tissues, bone and cartilage, guided support to reproduce the correct geometry and shape of the tissue is thought to be important. It is generally agreed that pore sizes of above 150 ⁇ m and preferably larger (Hulbert, et al., 1970; Klawitter, J.J, 1970; Piecuch, 1982; and Dennis, et al., 1992) and porosity greater than 50% are necessary for cell invasion of the carrier by bone forming cells. It has been further accepted that a tissue regenerating scaffold must be highly porous, greater than 50% and more preferably more than 90%, in order to facilitate cartilage formation.
- thrombi are formed and removed by blood elements, which are components of cascades regulating both coagulation and clot lysis.
- Blood elements which are components of cascades regulating both coagulation and clot lysis.
- Cells which are not terminally differentiated, such as fibroblasts migrate into the thrombus and lay down collagen fibers.
- Angiogenic cells are recruited by chemotactic factors, derived from circulating precursors or released from cells, to form vascular tissue.
- chemotactic factors derived from circulating precursors or released from cells
- angiogenesis factors appropriate for the type of tissue desired to be regenerated.
- U.S. 5,270,300 specifically teaches the use of TGF-beta in the matrix solution as a proliferation and chemotactic agent at a lower concentration and at a subsequent release of the same factor at a higher concentration to induce differentiation of cartilage repair cells.
- a membrane is secured between the bone-regenerating matrix and the cartilage-regenerating matrix to prevent blood vessel penetration from one site to the other site.
- U.S. Patent No. 5,607,474 to Athanasiou et al. describes a molded carrier device comprising two bioerodible polymeric materials having dissimilar mechanical properties arranged proximate to each other for the purpose of being placed in the body adjoining two dissimilar types of tissues.
- Each polymeric material has a variable degree of porosity or pore sizes into which tissue cells can enter and adhere.
- the two components of the device are fabricated separately and, e.g., bonded together in a mold. Other features, such as larger passages for cell access, can be mechanically placed in the device.
- U.S. Patent No. 5,514,378 attempts to address some of the requirements of providing a highly porous biocompatible and bioerodible device using a method of forming membranes from a polymer and particle solution.
- the pores are created by removing the particles, achieved by dissolving and leaching them away in a solvent, such as water, which does not dissolve the polymer, thereby leaving a porous membrane.
- the polymer must be soluble in a non-aqueous solvent and is limited to synthetic polymers.
- Once the membrane is created it may be cast into the desired shape. It is envisioned that such membranes could also be laminated together to form a three-dimensional shape.
- Osteoinductive materials include molecules derived from members of the transforming growth factor-beta
- TGF-beta gene superfamily including: bone morphogenetic proteins (BMPs) and insulin-like growth factors (IGFs).
- BMPs bone morphogenetic proteins
- IGFs insulin-like growth factors
- U.S. Patent No. 5,626,861 teaches a composite material for use as bone graft or implant composed of biodegradable, biocompatible polymer and a particulate calcium phosphate, hydroxyapatite.
- the calcium phosphate ceramic was added in order to increase the mechanical strength over the polymer alone and to provide a "bone bonding" material.
- the material is produced in such a manner as to provide irregular pores between 100 and 250 microns in size.
- the devices described in the above-referenced U.S. patents require multiple components to be made and either placed separately in the body or pre-assembled, resulting in a complicated manipulation at the time of implant in the first case or the danger that the juncture between device components will separate post-implantation in the others.
- these device lack a macroarchitecture or overall design that allows for the diffusion of oxygen, nutrients, and growth factors, in and out of the area in addition to a microarchitecture which creates a microenvironment which enhances cell growth and tissue regeneration.
- the devices disclosed herein are composite implantable devices having a gradient of one or more of the following: materials, macroarchitecture, microarchitecture, or mechanical properties, which can be used to select or promote attachment of specific cell types on and in the devices prior to and/or after implantation.
- the gradient forms a transition zone in the device from a region composed of materials or having properties best suited for one type of tissue to a region composed of materials or having properties suited for a different type of tissue.
- the devices are made in a continuous process that imparts structural integrity as well as a unique gradient of materials in the architecture.
- the gradient may relate to the materials, the macroarchitecture, the microarchitecture, the mechanical properties of the device, or several of these together.
- the devices disclosed herein typically are made using solid free form processes, especially three-dimensional printing process (3 DPTM).
- SFF solid free-form fabrication
- SLA stereo- lithography
- SLS selective laser sintering
- BPM ballistic particle manufacturing
- FDM fusion deposition modeling
- a gradient is formed of osteogenic and osteoconductive materials, such as calcium phosphates, to materials which are synthetic biocompatible polymers, such as poly(alpha)esters, which are particularly well suited for attachment of cells and controlled biodegradation.
- the devices have a
- the macroarchitecture or overall shape, can be of a design which allows fluid flow through and/or around one region and a different shape in another region with a gradient from one shape to the other.
- the microarchitecture may be from an osteoinductive system of interconnected pores to a system of staggered channels inductive to chondrocyte colonization.
- the gradient may relate to mechanical properties such as tensile or compressive strength. The gradient of properties may be from that which is suitable for weight bearing loads to one which is suitable for soft tissue regeneration.
- materials such as growth factors, which selectively encourage or enhance the growth or differentiation of cells that form tissues, can be incorporated on or in the device.
- a particularly favored method of fabricating the devices includes incorporating the factors in the structure of the device. Brief Description of the Drawings
- Figure 1 is a schematic view of the process of three-dimensional printing to make medical devices.
- Figure 2 shows a composite device for regeneration of cartilage which is implantable into bone.
- Figures 3a-g are cross-sectional (two-dimensional) shapes of the implantable devices.
- Figure 4 are schematics of a composite device (Figure 4f) of layers ( Figures 4a-e), showing a sectional view of the staggered channel design in Figure 4g (the dark regions represent polymer walls).
- Figures 5a-f show the channel design of cartilage devices made by layering sections with different channel sizes and openings formed using masks to guide the deposition of solvent, chloroform, which solidifies and binds the polymer together ( Figures 5a-e) to form a single composite ( Figure 5f).
- Figure 6a is a graph of the total collagen (micrograms) as a function of the porosity, either 90%) or 75%, of the scaffold, at one of four pore sizes, less than 38, 38-63, 63-106, and 106-150 microns.
- FIG. 6b is a graph of total sulfated glycosaminoglycan (micrograms) as a function of the porosity, either 90%) or 75%, of the scaffold, at one of four pore sizes, less than 38, 38-63, 63-106, and 106-150 microns.
- Three-dimensional devices with unconventional microstructures and macroarchitecture have been developed, which can be seeded and implanted immediately, seeded in an extracorporeal system prior to placement in the body, or implanted and seeded/or populated by ingrowth from adjacent tissue.
- the devices have advantages when applied to the construction of complex alloplasts or partial allografts designed for tissue regeneration at a physiological junction between two types of supporting tissue.
- devices manufactured as described herein which include gradients or transition zones that are designed for use in creating a composite of bone and cartilage are not susceptible to delamination of the bone portion from the cartilage portion caused by differential swelling of the polymeric materials or other properties, such as the hygroscopic nature of, or osmotic pressure generated by the placement of dry materials in a fluid filled cavity or other fluid containing site in the body, due to the integral nature of the device.
- devices manufactured as described herein which include gradients or transition zones that are designed for use in creating a composite of bone and cartilage are not susceptible to delamination of the bone portion from the cartilage portion caused by differential swelling of the polymeric materials or other properties, such as the hygroscopic nature of, or osmotic pressure generated by the placement of dry materials in a fluid filled cavity or other fluid containing site in the body, due to the integral nature of the device.
- the devices are constructed to maximize cell attachment, proliferation and/or differentiation as required for a particular purpose.
- the following variables can be manipulated to achieve the desired effect: macrostructure, chemical composition, microstructure including porosity, pore size (diameter), surface modifications such as surfactants and cell attachment peptides, incorporation of bioactive agents, flow properties (i.e., channels that direct and control fluid flow through and within the device), and structural elements on or in the device.
- Manipulation of the printing parameters and powder characteristics allow the design and fabrication of macroarchitecture, microarchitecture, and internal and surface characteristics.
- "Macroarchitecture" is used herein to mean the overall shape
- microarchitectural features is used herein to mean the internal structure that is preconceived and built into the device. Fine features, such as tortuous interconnected pores and surface patterning, are properties of the materials, processing, and finishing, but are not necessarily placed by design or by the three-dimensional printing process.
- the devices disclosed herein are a composite produced as a single part.
- the device has an overall shape that when placed in the body will compress slightly while allowing structural features for fluid movement within and without the device to be maintained, with channels and pores, suitable for implantation in the body at an interface between two types of tissues.
- One portion, such as the bone region of the composite device described herein, is specifically designed to address several functions. One of these is to encourage the migration of the blood and marrow-bourne tissue forming elements around and through the device, to maximize the surface- area-to-volume ratio in order to promote bone ingrowth, and to maximize compressive and torsional strength in order to provide the mechanical integrity needed to withstand the force of implantation.
- Minimization of material without sacrificing integrity of the device is considered desirable whenever possible in order to decrease the cost of goods required in production as well as to minimize the introduction of foreign substances into the body which could potentially evoke an immune response and which releases degradation by-products.
- the overall shape of the device is such that the device functions to allow the continued flow of dissolved nutrients in biological or biocompatible fluids through and around the device, thus minimizing the possibility of pressure differential across the device being formed by gas, fluid or temperature gradients.
- the device contains geometry, pores, and fluid communication channels that are conducive to cell migration, attachment, growth, and differentiation. These features can be manipulated to selectively populate a particular region(s) of the device with different cell
- the device can facilitate the regeneration of the complex supporting tissue interfaces that are characteristic of, for example, the cartilage coated surface of a long bone at the synovial interface.
- these devices can be engineered to allow and encourage growth of both osteogenic cells and chondrocytes, both of which are part of a naturally occurring cartilage-bone interface.
- Channels bounded by walls and consisting of substantially straight passageways of defined width, length, and orientation are a microarchitectural feature of the devices described herein. Staggered channels extending through the device and offset by 90° in different layers of the device are one particularly preferred embodiment. Staggering the channel and walls increases the strength of the device relative to a straight through channel design.
- the width of the channels can range from about 150 to 500 microns, with 250 microns preferred, in order to maximize the surface area available for cell seeding without compromising structural integrity or homogeneity of tissue formation.
- the channels facilitate the transport of nutrient to the cells and removal of cellular by-products and polymer degradation by-products which all may occur whether the device is colonized by cells before or after implantation in the body.
- the unique macroscopic staggered channels are designed to allow chondrocytes to contact the device throughout the thickness of the device not only superficially. This is important due to the limited migration capacity of the chondrocytes; the migration distances of this cell type being less than about 2 mm. Thus, when the device is seeded extracorporally, the chondrocytes may be placed directly into the center of the device.
- the porosity of a device will control the flow of nutrients to the colonizing cells as well as the surface area available for cellular attachment.
- pores of a minimum diameter of 60 microns or greater are required for angiogenesis in highly vascularized tissue, such as
- the devices are typically formed using synthetic polymeric materials.
- the device can include resorbable and/or non-resorbable materials, which can be positioned in various portions of the device during the manufacturing process.
- the materials forming one region are preferably osteoconductive and those materials forming a different adjacent region are preferably permissive to chondrocyte growth and maturation.
- Bioactive materials such as growth factors, can be incorporated on or in the device to select for growth, differentiation or proliferation of a particular cell type.
- Inserts in the device can also be used to manipulate cell attachment, proliferation and/or differentiation.
- an insert with a first portion designed to support cartilage healing and regeneration, and a second portion designed to anchor in and support bone regeneration can be incorporated into a device for use in treating osteochondral defects.
- the device is fabricated in a continuous process as a single part in which three regions, distinct in intent, design, and composition, are present: 1) a cartilage portion, 2) a bone portion and 3) a transition zone adjacent to and connecting both the cartilage and bone portions.
- the cartilage portion is about 90%> porous composed of synthetic polyester polymers containing staggered macro-channels of about 250 microns in diameter.
- the bone portion is from 25 to 55 %> porous and generally composed of both synthetic polymer and osteoconductive material in a shape permissive of fluid and gas flow at the outer edge of the device while maintaining contact with the host tissues.
- the transition zone which is adjacent to both the cartilage and the bone portions, forms a gradient in porosity from close to that of the bone or more dense portion to close to that of the cartilage or least dense portion.
- the transition zone may also form a gradient in polymer composition, from that of the bone portion to that of the cartilage portion, where the polymer is a copolymer and the ratio of monomers is different for the bone versus the cartilage portions, or the portions are formed of two different polymers and the transition zone is a blend or copolymer of the two polymers.
- the transition zone may also include a shape gradient or have a region which has an outer shape like the bone portion near the bone portion and a region with an outer shape that is substantially round or similar to the cartilage portion in the region nearest the cartilage portion.
- Surface finish is governed by the physical characteristics of the materials used as well as the build parameters. These factors include particle size, powder packing, surface characteristics of the particles and printed binder (i.e. contact angle), exit velocity of the binder jet, binder saturation, layer height, and line spacing. Interaction of the binder liquid with the powder surface, in particular, can be controlled carefully to minimize surface roughness. In a case where the binder becomes wicked out in a large area, the feature size control may be difficult, resulting in a rough surface.
- the device is manufactured using natural or synthetic structural materials that have inherent ability to encourage cell attachment, such as calcium phosphates, and provide mechanical integrity in terms of tensile strength and compressibility.
- the materials must be amenable to milling and sieving to produce specific particle sized powders, spreading of powder, and binding with solvent. Free powder must be removable from the device post- fabrication.
- Biocompatible is used herein to mean that the material degrades into components which may be resorbed by the body and which may be further biodegradable.
- Biodegradable materials are capable of being degraded by active biological processes such as enzymatic cleavage.
- Other properties desirable for materials to be used in the manufacture of the devices described herein include (1) solubility in a biologically acceptable solvent that can be removed to generally accepted safe levels, (2) capability of being milled to particles of less than 150 microns, and (3) elasticity and compressive and tensile strength.
- Synthetic polymers which have been found to be particularly suited to the present use include: poly(alpha)esters, such as: poly(lactic acid) (PLA) and poly(DL-lactic-co-glycolic acid) (PLGA). Other suitable materials include: poly(£ * -caprolactone) (PCL), polyanhydrides, polyarylates, and polyphosphazene.
- Natural polymers which are suitable include: polysaccharides such as cellulose, dextrans, chitin, chitosan, glycosaminoglycans; hyaluronic acid or esters, chondroitin sulfate, and heparin; and natural or synthetic proteins or proteinoids such as elastin,
- ⁇ 13- collagen ⁇ 13- collagen, agarose, calcium alginate, fibronectin, fibrin, laminin, gelatin, albumin, casein, silk protein, proteoglycans, Prolastin, Pronectin, or BetaSilk. Mixtures of any combination of polymers may also be used.
- Preferred synthetic polymers include: poly(hydroxy alkanoates), polydioxanone, polyamino acids, poly(g- ⁇ wm ⁇ -glutamic acid), poly(vinyl acetates), poly(vinyl alcohols), poly(ethylene-imines), poly(orthoesters), polypohosphoesters, poly(tyrosine-carbonates), poly(ethylene glycols), poly(trimethlene carbonate), polyiminocarbonates, poly(oxyethylene- polyoxypropylene), poly( ⁇ /p z ⁇ -hydroxy-carboxylic acid/polyoxyalkylene), polyacetals, poly(propylene fumarates), and carboxymethylcellulose.
- PLA/PLGA polylactic acid/polyglycolic acid
- a disadvantage is the production of acidic degradation products during degradation.
- PLGA 75:25 degrades rapidly in the body (4 to 5 months) but not as quickly as D,L-PLGA 50:50 (one to 2 months).
- other polymers with more slowly degrading properties may be blended with PLGA to produce a device capable of maintaining some physical properties for longer periods of time.
- Osteoconductive materials include: ceramics such as hydroxyapatite (HA), tricalcium phosphate (TCP), calcium phosphate, calcium sulfate, alumina, bioactive glasses and glass-ceramics, animal derived structural proteins such as bovine collagen, and demineralized bone matrix processed from human cadaver bone.
- Commercially available materials include: ProOsteon 500 (Interpore International), BoneSource (Orthofix) and OSTEOSET (Wright Medical Technology), Grafton Gel, Flex, and Putty (Osteotech), and Collagraft (Zimmer).
- Hyaluronic acid esters of benzyl or ethyl alcohol have suitable mechanical and degradation properties for use as either cartilage or blood vessel scaffolds and release few degradation products.
- Hyaluronic acid is
- Hyaluronate ester powder generation should be possible by the techniques of cryogenic milling or coacervation.
- Polyethylene oxide (PEO) is available in a wide range of molecular weights and may be used as a blending agent to modify the degradation properties of the polyesters and hyaluronic acid esters.
- Inorganic particles such as sodium chloride or tricalcium phosphate may be mixed with the polymer particles in the powder bed.
- Polymer Solvents The printing solution used may be a solvent for the polymer or contain a binder and may contain one or more dissolved additional polymers or other substances desired to be incorporated into the component. Preferred solvents are: water, chloroform, acetone, and ethanol.
- the binder can be a solvent for the polymer and/or bioactive agent or an adhesive which binds the polymer particles. Solvents for most of the bioerodible polymers are known, for example, chloroform or other organic solvents. Organic and aqueous solvents for the protein and polysaccharide polymers are also known, although an aqueous solution is preferred if required to avoid denaturation of the protein. In some cases, however, binding is best achieved by denaturation of the protein.
- the binder can be the same material as is used in conventional powder processing methods or may be designed to ultimately yield the same binder through chemical or physical changes that take place in the powder bed after printing, for example, as a result of heating, photopolymerization, chemical cross-linking, or catalysis.
- bioactive agents -15- polysaccharides, nucleic acids, lipids, and non-protein organic and inorganic compounds, referred to herein as "bioactive agents” unless specifically stated otherwise. These materials have biological effects such as growth factors, differentiation factors, steroid hormones, cytokines, lymphokines, antibiotics, and angiogenesis promoting or inhibiting factors.
- Bioactive agents also include compounds having principally a structural role, for example, hydroxyapatite crystals in a matrix for bone regeneration.
- the particles may have a size of greater than or less than the particle size of the polymer particles used to make the matrix. It is also possible to incorporate materials not exerting a biological effect such as air, radiopaque materials such as barium, or other imaging agents for the purpose of monitoring the device in vivo.
- cell adhesion factors such as laminin, pronectin, or fibronectin or fragments thereof, e.g. arginine-glycine- aspartate
- the device may also be coated or have incorporated cytokines or other releasable cell stimulating factors such as; basic fibroblast growth factor (bFGF), transforming growth factor beta (TGF-beta), nerve growth factor (NGF), insulin-like growth factor- 1 (IGF-1), growth hormone (GH), multiplication stimulating activity (MSA), cartilage derived factor (CDF), bone morphogenic proteins (BMPs) or other osteogenic factors, anti-angiogenesis factors (angiostatin),
- bFGF basic fibroblast growth factor
- TGF-beta transforming growth factor beta
- NGF nerve growth factor
- IGF-1 insulin-like growth factor- 1
- GH growth hormone
- MSA multiplication stimulating activity
- CDF cartilage derived factor
- BMPs bone morphogenic proteins
- osteogenic factors anti-angiogenesis factors
- exogenously added cells or exogenously added factors including genes may be added to the implant before or after its placement in the body.
- cells include autografted cells which are derived from the patients tissue and have (optionally) been expanded in number by culturing ex vivo for a period of time before being reintroduced.
- Cartilage tissue may be harvested and the cells disaggregated therefrom, and cultured to provide a source of new cartilage cells for seeding the devices.
- the devices may also be seeded with cells ex vivo and placed in the body with live cells attached thereto.
- DNA of a gene sequence, or portion thereof, coding for a growth factor or other of the auxiliary factors mentioned above may also be
- the DNA sequence may be "naked” or present in a vector or otherwise encapsulated or protected.
- the DNA sequence may also represent an antisense sequence of a gene or portion thereof.
- bioactive agents that can be incorporated into the devices. Those materials which can be processed into particles using spray drying, atomization, grinding, or other standard methodology, or those materials which can be formed into emulsions, microparticles, liposomes, or other small particles, and which remain stable chemically and retain biological activity in a polymeric matrix, are preferred.
- SFF solid free-form fabrication
- SFF methods can be used to selectively control composition within the build plane by varying the composition of printed material.
- the SFF methods can be adapted for use with a variety of polymeric, inorganic and composite materials to create structures with defined compositions, strengths, and densities, using computer aided design (CAD). This means that unconventional microstructures, such as those with complicated porous networks or unusual composition gradients, can be designed at a CAD terminal and built through an SFF process such as 3DP.
- CAD computer aided design
- 3 DP uses a process of spreading powder and depositing binder onto a powder bed. Three-dimensional printing is described by Sachs, et al., "CAD-Casting: Direct Fabrication of Ceramic Shells and Cores by Three- dimensional Printing: Manufacturing Review 5 (2), 117-126 (1992) and U.S.
- Patent No. 5,204,055 the teachings of which are incorporated herein.
- Suitable apparatuses include both those with a continuous jet stream printhead and a drop-on-demand (DOD) printhead.
- 3DP can be used to create a porous bioerodible matrix for use as a medical device as taught in U.S. Patent Nos. 5,490,962 and 5,518,680 to Cima, et al., the teachings of which are incorporated herein by reference.
- a continuous-jet head provides for a fluid that is pressure driven through a small orifice. Droplets naturally break off at a frequency that is a function of the fluid's properties and the orifice diameter. Multiple jet heads are preferred.
- a DOD printhead utilizes individual solenoid valves that run at frequencies up to 1.2 kHz. Fluid is pressure driven through these valves, and a small orifice is downstream of the valves to ensure accurate and repeatable droplet size.
- raster and vector apparatuses can be used.
- DOD a raster apparatus provides that the printhead goes back and forth across the bed with the jet turning on and off.
- a continuous-jet head is always on, and a vector apparatus is used similar to an x-y printer.
- 3DP is used to create a solid object by ink-jet printing a binder onto selected areas of sequentially deposited layers of powder or particulates, as shown in Figure 1, discussed in more detail below.
- the terms "powder” and “particulates” are used interchangeably. Each layer is created by spreading a thin layer of powder over the surface of a powder bed.
- a moveable powder piston is located within a cylinder, with a powered roller to deliver dispensed powder to a receiving platform located adjacent to the powder feeder mechanism.
- the feed piston is raised a predetermined amount for each increment of powder delivery.
- the roller then sweeps across the surface of the powder feeder cylinder and deposits it as a thin layer across the receiving platform immediately adjacent to the powder feeder.
- the powder feeding piston is then lowered as the roller is brought back to the home position, to prevent any back delivery of powder.
- the powder piston and cylinder arrangement can also consist of multiple piston/cylinders located in a common housing, which could be used to dispense multiple powders in the following sequence: 1. Line up the first desired powder cylinder with the rolling/delivery mechanism; 2. Raise incrementally the movable position piston to deliver an incremental amount of powder; 3. Activate the roller to move the powder to a receiving platform;
- This method of powder feeding can be controlled manually or be fully automated. Cross contamination of different powders is minimized since each powder is contained in its own separate cylinder.
- One of the advantages to this method is that only one piston raising/lowering mechanism is required for operation, regardless of the number of powder cylinders. By raising the powder for delivery rather than dropping it from above, problems associated with gravity based delivery systems such as "ratholing”, incomplete feed screw filling/emptying and “dusting” with the use of fine powders is eliminated or minimized since only enough energy is introduced to move the powder up an incremental amount.
- the powder feeder housing, with its multiple cylinders and pistons can also be designed as a removable assembly, which minimizes changeover times from one powder system to another.
- the powder bed is supported by a piston that descends upon powder spreading and printing of each layer (or, conversely, the ink jets and spreader are raised after printing of each layer and the bed remains stationary).
- Instructions for each layer are derived directly from a computer-aided design (CAD) representation of the component.
- the area to be printed is obtained by computing the area of intersection between the desired plane and the
- FIG. 1 CAD representation of the object.
- the individual sliced segments or layers are joined to form the three-dimensional structure.
- the unbound powder supports temporarily unconnected portions of the component as the structure is built but is removed after completion of printing.
- the 3DP process is shown schematically in Figure 1, wherein a 3DP apparatus is indicated generally by the number 10. Powder 12 is rolled from a feeder source (not shown) in stage I with a powder spreader 14 onto a
- the thickness of the spread layer is varied as a function of the type of dosage form being produced. Generally, the thickness of the layer can vary from about 100 to about 500 microns, and more typically from 100 to about 200 microns.
- the printhead 22 then deposits the binder (fluid) 24 onto the powder layer and the build piston 26 is lowered one layer distance. Powder is again rolled onto the build bed 18 and the process is repeated until the dosage forms are completed (stages 2 and 3 of Figure 1).
- the droplet size of the fluid is from about 50 to about 500 microns in diameter and more typically greater than 80 microns.
- Servomotors (not shown) are used to drive the various actions of the apparatus 10.
- Construction of a 3DP component can be viewed as the knitting together of structural elements that result from printing individual binder droplets into a powder bed. These elements are called microstructural primitives.
- the dimensions of the primitives determine the length scale over which the microstructure can be changed. Thus, the smallest region over which the concentration of bioactive agent can be varied has dimensions near that of individual droplet primitives.
- Droplet primitives have dimensions that are very similar to the width of line primitives formed by consecutive printing of droplets along a single line in the powder bed. The dimensions of the line primitive depend on the powder particle dimension and the amount of binder printed per unit line length.
- a line primitive of 500 micron width is produced if an inkjet depositing IJ cc/min of methylene chloride is made to raster at 8 "/sec over the surface of a polycaprolactone (PCL) powder bed with 45-75 micron particle size.
- PCL polycaprolactone
- Higher printhead velocities and smaller particle size produce finer lines.
- the dimensions of the primitive seem to scale with that calculated on the assumption that the liquid binder or solvent needs to fill the pores of the region in the powder which forms the primitive. Finer feature size is also achieved by printing polymer solutions rather than pure solvents. For example, a 10 wt.% PCL solution in chloroform produces 200 micron lines under the same conditions as above.
- the layers become hardened or at least partially hardened as each of the layers is laid down.
- the form and its contents be heated or cured at a temperature selected to further promote binding of the powder particles.
- the loose unbonded powder particles may or may not be removed using a suitable technique such as ultrasonic cleaning, to leave a finished device.
- the solvent drying rate is an important variable in the production of polymer parts by 3 DP. Very rapid drying of the solvent tends to cause warping of the printed component. Much, if not all, of the warping can be eliminated by choosing a solvent with a low vapor pressure. Thus, polycaprolactone (PCL) parts prepared by printing chloroform have nearly undetectable amounts of warpage, while large parts made with methylene chloride exhibit significant warpage. It is often convenient to combine solvents to achieve minimal warping and adequate bonding between the particles. Thus, an aggressive solvent can be mixed in small proportions with a solvent with lower vapor pressure.
- PCL polycaprolactone
- 3 DP requires the use of polymer particles or powder.
- the minimum final feature dimension of the work product will be dependent on the initial particle size of the powder material used. That is, the process of joining at least two particles by printing a drop of solvent thereon means that the minimum feature size is approximately twice the particle size. Aggressive solvents tend to nearly dissolve the particles and reprecipitate dense polymer
- the devices include either a gradient or a transition zone, which can itself be a gradient.
- the gradient can be a gradient of materials or material mixtures. Using a gradient of materials allows the physical properties of the resulting structures to change gradually, thereby mitigating large discontinuities which can lead to disruption of or performance failure by the device.
- Such physical properties of the materials include thermal expansion coefficient, elasticity, and swelling.
- bioactive agent there are two principal methods for incorporation of bioactive agent into the device: as a dispersion within a polymeric matrix and as discrete units within a discrete polymeric matrix.
- the bioactive agent preferably is applied in the polymer particle binder; in the second method, the bioactive agent is applied in a non-solvent for the polymer particles.
- the selection of the solvent for the bioactive agent depends on the desired mode of release and the compatibility of the bioactive agent in the solvent.
- the solvent is selected to either dissolve the matrix or is selected to contain a second polymer which is deposited along with the bioactive agent.
- the printed droplet locally dissolves the polymer powder and begins to evaporate.
- the bioactive agent is effectively deposited in the polymer powder after evaporation since the dissolved polymer is deposited along with the agent.
- the latter case where both the drug and a polymer are dissolved in the printed solution, is useful in when the powder layer is not
- Binding is achieved by deposition of the binder, in this case the polymer, at the necks between the powder particles so that they are effectively bound together along with the bioactive agent.
- Devices may be fabricated with bioactive-rich regions within the device. In this case, multiple printheads are used to deposit active containing solvent in selected regions of the powder bed. The remaining volume of the desired device is bound with pure solvent deposited by a separate printhead.
- the devices also simply may be coated with the bioactive agent or have the agent placed therein or thereon.
- the bioactive agent may be covalently or noncovalently attached to the device.
- SFF solid free-form fabrication
- Stereolithography is based on the use of a focused ultra-violet (UV) laser which is vector scanned over the top of a bath of a photopolymerizable liquid polymer material.
- the UV laser causes the bath to polymerize where the laser beam strikes the surface of the bath, resulting in the creation of a first solid plastic layer at and just below the surface.
- the solid layer is then lowered into the bath and the laser generated polymerization process is repeated for the generation of the next layer, and so on, until a plurality of superimposed layers forming the desired device is obtained.
- SLS also uses a focused laser beam, but to sinter areas of a loosely compacted plastic powder, the powder being applied layer by layer.
- a thin layer of powder is spread evenly onto a flat surface with a roller mechanism.
- the powder is then raster-scanned with a high-power laser beam.
- the powder material that is struck by the laser beam is fused, while the other areas of powder remain dissociated.
- Successive layers of powder are deposited and raster-scanned, one on top of another, until an entire part is complete. Each layer is sintered deeply enough to bond it to the preceding layer.
- -23- BPM uses an ink-jet printing apparatus wherein an ink-jet stream of liquid polymer or polymer composite material is used to create three- dimensional objects under computer control, similar to the way an ink-jet printer produces two-dimensional graphic printing.
- the device is formed by printing successive cross-sections, one layer after another, to a target using a cold welding or rapid solidification technique, which causes bonding between the particles and the successive layers.
- FDM employs an x-y plotter with a z motion to position an extrudable filament formed of a polymeric material, rendered fluid by heat or the presence of a solvent
- Example 1 Use of Three-dimensional Printing Techniques to Construct a
- a bone replacement part designed to assure mechanical strength, density, and weight similar to that of bone logically may be assumed to require the appearance of cancellous bone in both internal and external structure.
- the healing process occurs in several stages and bone formation requires, in some cases, that cellular precursors undergo migration and differentiation before new bone is formed.
- the objective of a bone tissue or cartilage tissue healing device is not to imitate the configuration of the final tissue structure but rather to encourage and enhance the natural tissue formation process while contributing mechanical strength in the area to be regenerated.
- 3DP like any process, has limitations imposed by the nature of the materials and the apparatus used.
- Figure 2 is a schematic of an implantable composite device for implantation into a bony site for regeneration of cartilage.
- the dark regions in the layers are holes that create the staggered channels.
- Layers 23-28 are transition layers, then layers 29-38, forming a thickness of 2 mm, are for
- Layers 1-26 use a 1 cm cloverleaf stencil, and layers 27-38 use the 1 cm disk stencil. Two layers of each design are made for the cartilage region.
- Figures 3a-g show the shapes contemplated for the two-dimensional cross section of a portion of the device, typically the portion intended to reside within bone. Designs contemplated for the bone portion of the composite device were analyzed on the basis of selected criteria including compressive strength, surface area available for cell adhesion, and ease of fabrication. Other criteria such as the ability to fabricate the device using masking rather than computer controlled printing were also considered for initial ease of prototype production. The specific criteria is shown in Table 1. Table 1: Decision Matrix for Design of Bone Portion
- the two designs having the highest number of positive features are the hollow cylinder and the clover design, both of which can be fabricated with masks.
- the honeycomb design is another candidate for fabrication using inkjet printheads for drop-on-demand of organic solvents.
- the honeycomb design enables maximizing both surface area and void volume for tissue ingrowth and biological interaction while maintaining high uniaxial strength.
- Example 2 Determination of Optimal Pore Size and Porosity.
- the devices described herein must be porous but retain strength, as well as be composed of osteoconductive materials. Therefore, the
- a modified leaching protocol was adopted to approximate more closely the seeding and culture conditions to which the devices would be subjected.
- CO 2 dried samples were placed into a Nalgene bottle that contained a minimum of 20 ml of water per sample. The bottle was placed onto an orbital shaker (model 3527, Lab-Line Environ, Melrose Park, IL) at lOO rpm and 37 °C. The water was replaced every hour. After five hours, the NaCl content in the solution was evaluated using silver nitrate for white precipitate that indicates NaCl. If NaCl was detected, leaching was continued until none was detected. Samples were removed, blotted dry, and placed into a vacuum desiccator overnight to complete drying. Leaching can also be performed using a ball mill apparatus at room temperature. The porosity of the devices was determined by the mass loss upon leaching the NaCl out of the device. This was done by measuring the dry mass of the devices before and after leaching.
- the porosity was varied between the two tissue specific regions of the device. In the region designed specifically to enhance cartilage regeneration, the porosity was maximized (> 90%) to promote cell attachment and proliferation and allow space for formation of extracellular matrix. Highly porous structures have a high surface-to-volume ratio.
- -26- surface area maximizes available sites for cell attachment while minimizing the amount of material used.
- Minimizing material besides allowing space for living components and promoting homogeneous formation of tissue, also minimizes the non-living foreign material which can cause immune response and produces potentially detrimental degradation by-products.
- the device In the region of the device designed specifically to be implanted in bone, the device was less porous in order to provide for more mechanical strength and to discourage attachment of chondrocytes.
- the materials selected for this region are slowly degrading bioresorbable materials with an initially large pore size created by leaching out salt particles of 125 microns or greater. A gradient of porosities is achieved by altering the salt content of the powder bed in successive layers.
- PCL Poly( ⁇ -caprolactone)
- the PCL as received (Birmingham Polymers, lot D96157, 200,000 MW) was cryogenically milled and sieved to a particle size below 150 ⁇ m. There was approximately a 10% yield from the milling process. Optical micrographs revealed most particles to be near the upper size limit. Particle size analysis (Amherst Process Instruments, Amherst, MA) showed the average size to be 115 + 2 ⁇ m assuming a spherical shape. Many particles were oblong and longer than the upper screen size, indicating a large degree of shear during the milling process.
- Powder mixtures were prepared with the following compositions: 1. 100% PCL [ ⁇ 150 ⁇ m] 2. 90% NaCl [125-150 ⁇ m], 10% PCL [ ⁇ 150 ⁇ m]
- Binder test - The use of chloroform with the continuous jet nozzle was found to produce a steady flow rate of 1 J ml/min at 20 psi.
- Line test - Base powder beds were prepared 2 mm deep, and chloroform binder flow was established at 1.2 ml/min. Lines of velocities between 0.75 m/s and 1.5 m/s were executed on pure PCL powder and the two powder mixtures. Ballistic and bleeding effects were minor at all print speeds. The smallest line generated using pure PCL powder was 480 ⁇ m in diameter, and the largest line was 670 ⁇ m in diameter. Line size could not be measured for the 90% NaCl powders because the fragile samples could not be retrieved from the powder bed, even when printed at lower speeds. Ribbon test -Base powder beds were prepared and binder flow was established as for the line test.
- Ribbons 20 mm in length and 3 mm in width were fabricated with all of the powder mixtures using velocities between 0.75 m/s and 1.5 m/s, and line spacings between 75 and 150 ⁇ m. Optimal parameters were chosen such that bleeding was minor and a ribbon sample could be recovered from the bed.
- Optimal parameters were 125 cm/s velocity and 100 ⁇ m line spacing for pure and 10% PCL powders, and 100 cm/s velocity and 100 ⁇ m line spacing for the 5% PCL mixture. Ribbons fabricated with the pure PCL powder showed excellent strength; however, particle dissolution was incomplete. Double-printing the ribbon yielded particles that were more
- Double-printing is applied, in general, when processing large polymer particles (>100 ⁇ m) for enhanced dissolution and improved bonding.
- Wall test The data from this test in conjunction with the line test was used to determine the minimum feature size and optimum printing resolution that could be expected with the powder and binder.
- This final test included fabricating walls by printing a set of lines on multiple layers. Walls of one, two, and three adjacent line widths were fabricated with the 90% NaCl: 10% PCL mixture. The horizontal spacing between adjacent lines within the walls was 100 ⁇ m and the vertical layer spacing was 180 ⁇ m. The print velocity was 125 cm/s, and the chloroform binder flow rate was 1.2 ml/min. The resulting wall thickness was 0.52, 0.58, and 0.79 mm for walls of single-, double-, and triple-line widths, respectively.
- Example 3 Mixtures of PLGA, CaP and NaCl to make porous devices. Three powders: slow degrading PLGA (D,L-PLGA (85:15)), tri- calcium phosphate (CaP), and NaCl, mixed together, would not yield mechanically strong devices. Therefore, CaP and PLGA were coacervated with the NaCl. The NaCl was dissolved in a solvent and the CaP suspended in the polymer solution.
- the coacervated material was sealed in the vessel and chilled to 10°C.
- the vessel was filled with liquid CO 2 to a pressure of 750-800 psi.
- the outlet valve was opened to allow a 10 minute continuous vent at 20 SCFH. Following the vent period, the outlet valve was
- L-PLGA (85:15) was used to avoid the problem of polymer decomposition during milling.
- L-PLGA unlike D,L-PLGA, is crystalline and has a higher melting point.
- TGA ThermoGravimetric Analysis
- Example 4 Preparation of a Bone Device from a PLGA Coacervate.
- Polymer and bone composites were fabricated by three different methods: (1) mixing pure powders of bone and polymer in the powder bed in
- the milling chamber was partially filled with liquid nitrogen, a slurry of liquid nitrogen and powder was introduced, and the milling commenced.
- the liquid nitrogen maintains the polymer temperature below the glass transition temperature (Tg) during the milling process.
- Tg glass transition temperature
- the processed powder was collected, dried in a vacuum oven for 24 hours, and mechanically sieved for 1 hour to classify the powder into distinct particle sizes.
- Bovine cortical bone was sectioned into 3 to 5 mm blocks for cryogenic milling as described. The milled bone was dried and sieved with a yield of 50%> bone powder in the 20 - 45 ⁇ m range and 15% less than 20 ⁇ m.
- the production of a bone and polymer coacervate was achieved using well known technology in the field of ceramic fabrication, that used to produce ceramic greenware.
- the process is similar to microencapsulation techniques.
- Particles, in this case bone rather than ceramic are dispersed in the polymer solution in such a manner as to cause the bone particles to become coated with polymer and to remain suspended in the polymer solvent.
- the coated particles are precipitated into a uniform mass of material by addition of a non-solvent for the polymer.
- bone powder (20 - 45 ⁇ m) was dispersed in a polymer solution (5- 10% PLGA by weight in chloroform) to form a 1 : 1 mixture of bone and polymer. Sonication at 25 MHz for 5 minutes uniformly dispersed the bone particles.
- Isopropanol was then added to a final volume ratio of 3:1 of suspension sopropanol to harden the polymer and produce the coacervate.
- the solid was collected, filtered, and dried under vacuum.
- the coacervate was then milled to produce bone particles and polymer typically in the 50 ⁇ m range.
- the coacervate material was used in the powder bed with chloroform used as the printing material.
- the placement of the droplets was accomplished by using masks of thin stainless steel plates with laser-cut holes in the pattern desired to be printed.
- the material was used successfully to fabricate devices with defined channel architecture.
- the devices were approximately 50 weight percent bone and 60 volume percent bone.
- the compressive elastic modulus of the devices are about 50 GPa.
- Example 5 Porous devices of Polymer and CaP created by salt leaching.
- compositions containing polymer and inorganic particles as tri-calcium phosphate were compared.
- One composition was 35% NaCl and a 2: 1 ratio of PLGA to TCP (35% porous);the other was 45% NaCl and a 3 : 1 ratio of PLGA to TCP (45% porous).
- two methods of calculating salt loss from the composition were used on devices leached in water using agitation produced either by a ball mill or an orbital shaker.
- the CO 2 dried samples were placed in 20 ml of water and placed either in a ball milling device (U.S. Stoneware, East furniture, OH) or onto an orbital shaker (Model 3527, Lab-Line Environ, Melrose Park, IL) at 100 rpm and 37° C. The water was replaced each hour and the water
- Elemental analysis was performed on bone devices leached by both methods in order to quantitate the extent to which NaCl had been removed from the compositions of the devices.
- the polymer, NaCl, water, and air volume fractions during leaching of bone devices were measured on device leached using the orbital shaker.
- composition calculations derived from these measurements were not strictly comparable to that based on elemental analysis at all time points.
- the data at three hours conelated well despite the difference in leaching conditions, with the NaCl content at 6%> for the 35% sample and 23% for the 45% sample.
- Discrepancy between the NaCl values occurred in the compositions calculated from the data for longer leaching periods.
- Possible sources of enor in the water infiltration study include: 1) the devices may not have been fully dried in the dry weight measurements, 2) the device dimensions included stilts, 3) the assumption that the devices were perfect cylinders, and 4) the density values used for the polymer, NaCl, and TCP.
- Example 6 Mechanical Strength of Porous Devices containing inorganic particles.
- the mechanical properties of bone device implants containing PLGA, TCP, and NaCl were investigated in this study.
- the L-PLGA used was an (85:15) copolymer of 242,000 MW (Lot D97157, Birmingham Polymers Inc.) milled to 38-150 ⁇ m.
- the TCP (Lot 95HO644, Sigma) was used in the
- Tensile Testing Tensile testing specimens were fabricated with dimensions conforming to ASTM standard D 638-96. Custom-manufactured masks were used to generate samples of the appropriate dimensions as described in Figure 2. An Instron Testing machine 4201 was used for both tensile and compression testing. Pneumatic grips (Instron type 2712) were used to hold the specimens in place with an external air pressure of 30 psi. This pressure produced some deformation of the wide section of the sample.
- Compression Testing was canied out according to the ASTM D 695-96 standard. This protocol recommended using a cylindrical specimen with a length twice its diameter. Cylindrical samples were fabricated of size 6 mm diameter and 12 mm length for use in this study. Five specimens of each composition were subjected to this test using the same Instron as for the above tensile tests. After removing surface abenations using fine sandpaper, the samples were placed between the faces of a compression platen on the top and a compression anvil on the bottom (Instron, cat. no. 2501-107 for the upper platen, 2501-085 for the lower anvil). Compression was canied out to between 1% and 20% strains at a rate of 0.5 mm/min.
- the specimen was unloaded in a controlled manner and the hysteresis recorded. Uniform deformation was assumed. The initial cross-sectional area was used in the following calculations. The compressive strength was defined as the point at which lines from the initial linear region and terminal linear region intersected. The elastic modulus was obtained as in the tensile test.
- Example 7 Polymeric Components with Channel Architecture.
- materials selection and macroscopic architecture The materials composition was selected to yield a high porosity and to degrade within several weeks.
- Two primary polymer combinations involving PLGA and PLA were evaluated for their use in cartilage devices.
- Two variants of macroscopic staggered channel architectures were developed.
- the objective of the macroscopic channels was to facilitate cell seeding and proliferation.
- the desired macroscopic channel size was chosen to be approximately 200 ⁇ m to maximize the surface area available for cell seeding without compromising structural integrity or homogeneous tissue formation.
- This batch of cartilage devices refened to as Batch A, included a 1 : 1 ratio of D,L-PLGA (50:50) 50,000 MW (Boehringer Ingelheim) with free acidic side chains to L-PLA 27,000 MW (Birmingham Polymers).
- the polymer particle size was 63-106 mm.
- PLGA with free acidic side chains was chosen to increase the rate of degradation of the device since previous results with standard PLGA suggested that faster degradation may be desirable.
- a 90 wt% NaCl and 10% PLA-PLGA mixture was used to obtain high porosity. The pore sizes were expected to be larger than the NaCl particle size, which was 106-150 mm.
- Grooves were formed by not depositing chloroform on sections 0.675 mm in width within the layer. The grooves were spaced 2.05 mm apart. Sixteen holes were constructed on the top face of the device superposed over the grooves. These holes were formed by printing a layer of grooves, rotating the print bed 90°, and printing another set of grooves without spreading additional powder. This effectively double- printed a significant portion of device matrix with chloroform. Double- printing may also improve mechanical properties of the final device by more completely dissolving the polymer and thus create a stronger bond between the polymer particles. The channel size was observed to be 182 ⁇ 37 ⁇ m in the actual devices. The drawback of this architecture design is that the two sets of grooves lie parallel to each other, potentially causing a structural
- FIG. 5f shows a schematic cross-section of a Batch B device.
- the macroscopic channels are the dark regions outlined in the upper corners.
- Devices having structures consisting of an upper cartilage component, a transition zone, and a lower bone component for insertion and anchoring into the underlying bone of osteochondral defects were made.
- the materials used in the bone portion of the cartilage-bone composite are a slow degrading PLGA, tri-calcium phosphate (CaP), and NaCl.
- the NaCl was leached out to form micropores in the final device.
- a trial batch of cartilage-bone composite devices was fabricated with a bone region, a transition region, and a cartilage region with macroscopic channels identical to that of Cartilage Batch A.
- the overall dimensions of the product were 8 mm X 1 cm before drying and salt leaching.
- the objective of this development batch was to evaluate the lamination and mechanical integrity of the final device.
- the channels were a nominal 0.675 mm square and were spaced 2.05 mm. Two layers of channels were separated by three layers of walls, 1.375 mm wide and spaced 2.05 mm. A detachable print plate was used to allow rotation of the powder bed underneath the stencil. Each channel layer included printing on the non-rotated and the rotated powder bed. A manual roller was used to spread powder.
- Stilts were constructed of three layers 200 ⁇ m each. Stilts were printed in a crosshair configuration, with two adjacent lines per leg. The polymer combination for region 1 made up the stilts and the bone portion of the device (layers 1 to 22). A 1-cm cloverleaf stencil was used for the bone and first two transition regions. Powder combinations for regions 2, 3, and
- the powder combination for region 5 made up the cartilage portion of the device, which included 10 layers of channel architecture.
- the architecture for region 5 used the design shown in FIG. 5 and as described for Cartilage Batch B in Example 6. Construction of channels required printing on a layer then rotating the plate
- the top right corner of the plate was registered to the walls of the piston housing.
- the 16 channels ananged in a 4 x 4 anay were nominally 0.675 mm square and were spaced 2.05 mm apart.
- Two layers of channels were separated by two layers of transition channels.
- the transition channels were similar to normal channels, but were nominally 0.675 mm wide and 1.90 mm long.
- the resulting cartilage-bone composite devices included a unique macroscopic architecture in addition to the gradients of materials.
- the bottom of the device was approximately 5 mm thick and was fabricated with a cloverleaf stencil for enhanced bone ingrowth. The next six layers included the transition region with the bottom four layers using the cloverleaf stencil.
- the top two layers of the transition region used the disk stencil to avoid mechanical strength concerns.
- the top 2 mm of the composite, the cartilage region was fabricated with macroscopic staggered channel architecture. Minor modifications were made to enhance the structural integrity of the device. For increased support, thin walls were added in the long grooves. The grooves were also rotated 90° with respect to each other.
- L-PLA has a glass transition temperature of 57-65°C
- D,L-PLGA (50:50) undergoes a glass transition near 45-55°C.
- Devices made with a 1:1 ratio of D,L-PLGA(50:50) 50,000 and L-PLA 27,000 have a glass transition temperature of approximately 53°C.
- the polymer in the device contains residual elastic strain around the NaCl particles. When this supporting NaCl is leached out, the polymer may partially collapse, resulting in shrinkage of the overall dimensions of the device possibly due to the hydrostatic pressure to which the devices are subjected during the leaching process.
- D,L-PLGA (50:50) 50,000 MW and L-PLA 27,000 MW was used for the cartilage region.
- the transition region included a gradient of NaCl from 85%) to 65%, of 1:1 PLGA:PLA from 10% to 5%, and a gradient of L-PLGA (85:15) 242,000 MW from 5% to 30%, from the cartilage region to the bone region.
- the bone region was fabricated with 55% NaCl and a 3 : 1 ratio of
- Macroscopic staggered channels in the cartilage portion of the device allow chondrocytes to be seeded in vitro
- the staggered channel design facilitates chondrocyte seeding directly into the center of the cartilage portion of the device. More homogeneous seeding promotes faster homogeneous cartilage formation.
- the staggered channels facilitate the transport of nutrients to the cells and removal of cellular byproducts and polymer degradation by-products away from the cells during culture in cell growth media.
- the bone implantable portion of the device does not have staggered channels for two reasons: osteocytes are highly migratory and therefore do not need such a configuration and to impart mechanical strength to this portion of the device. The latter property is an important characteristic enabling the device to withstand the forces of surgical implantation.
- Example 9 Scaffolds for use as tissue engineered substitutes.
- Human- or animal-derived cells were cultured on scaffolds statically or dynamically for up to eight weeks. Analyses were customized per engineered tissue (quantitative MTT and DNA tests for metabolic activity and cell number, respectively; DMMB assay for glycosaminoglycans, Sirius Red assay for collagen, image analyses for pre- and post-culture dimensions, scaffold and tissue mechanics, and qualitative immunostaining and histology). The data showed that human and animal cell types adhered to,
- Example 10 Tissue engineered cartilage constructs.
- PLLA scaffolds of varying porosity and pore size were fabricated using the three-dimensional printing process described above.
- the macroporous structure in the scaffolds was created by incorporation of a porogen, NaCl, followed by leaching of NaCl from the scaffolds.
- the porosity of the scaffolds was controlled by altering the weight ratio of polymer to NaCl particles incorporated into the scaffold.
- scaffold pore size was controlled by using NaCl of specified particle sizes in the fabrication process.
- the NaCl particles used in the scaffold fabrication were sieved into sizes ⁇ 38, 38-63, 63-106, and 106-150 microns to create scaffolds with pore sizes defined by these particle sizes.
- One batch of scaffolds was made at each pore size range for each of the two porosities. Scaffolds were 10 mm in diameter and 2 mm thick.
- Pore size of the scaffolds did not have a significant effect on any of the quantitative measurements (DNA, S-GAG, and collagen) for both porosities.
- scaffolds of both porosities allowed for more homogeneous cell seeding and uniformly distributed matrix with increasing pore size.
- the results demonstrate that tissue engineered constructs may be modified by controlling the scaffold architecture.
- 3DP scaffolds composed of 90% porous PLLA contained equivalent cartilage matrix levels as compared to PGA scaffolds.
- chondrocytes deposited much less (p ⁇ 0.05) hyaline-like matrix in the 75%o porous TheriForm scaffolds. More uniform cell seeding and deposition of safranin-O stained matrix was found in the scaffolds of greater pore sizes.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000575451A JP2002527144A (en) | 1998-10-12 | 1999-10-12 | Composite for tissue regeneration and method for producing the same |
AU64271/99A AU768641B2 (en) | 1998-10-12 | 1999-10-12 | Composites for tissue regeneration and methods of manufacture thereof |
CA002345982A CA2345982A1 (en) | 1998-10-12 | 1999-10-12 | Composites for tissue regeneration and methods of manufacture thereof |
EP99951941A EP1121072A1 (en) | 1998-10-12 | 1999-10-12 | Composites for tissue regeneration and methods of manufacture thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10385398P | 1998-10-12 | 1998-10-12 | |
US60/103,853 | 1998-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000021470A1 true WO2000021470A1 (en) | 2000-04-20 |
Family
ID=22297358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/023732 WO2000021470A1 (en) | 1998-10-12 | 1999-10-12 | Composites for tissue regeneration and methods of manufacture thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US6454811B1 (en) |
EP (1) | EP1121072A1 (en) |
JP (1) | JP2002527144A (en) |
AU (1) | AU768641B2 (en) |
CA (1) | CA2345982A1 (en) |
WO (1) | WO2000021470A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1064958A1 (en) * | 1999-06-30 | 2001-01-03 | Ethicon, Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
EP1234587A1 (en) * | 2001-02-26 | 2002-08-28 | Ethicon, Inc. | Biocompatible foam composite |
FR2828408A1 (en) * | 2001-08-09 | 2003-02-14 | Asahi Optical Co Ltd | Implant forming method e.g. artificial skull bone involves forming layer of ingredient powder, applying reactant liquid to layer to harden specific portions |
WO2003037607A1 (en) * | 2001-10-29 | 2003-05-08 | Therics, Inc. | A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form |
WO2003045460A1 (en) * | 2001-11-27 | 2003-06-05 | Takiron Co., Ltd. | Implant material and process for producing the same |
WO2004010907A1 (en) * | 2002-07-29 | 2004-02-05 | Therics, Inc. | A complex three-dimensional composite scaffold resistant to delamination |
EP1452191A2 (en) * | 1999-06-30 | 2004-09-01 | Ethicon, Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
EP1642599A1 (en) * | 2003-05-26 | 2006-04-05 | PENTAX Corporation | Porous composite containing calcium phosphate and process for producing the same |
EP1366718A3 (en) * | 2002-05-31 | 2006-04-19 | Ethicon, Inc. | Attachment of absorbable tissue scaffolds to fixation devices |
EP1733746A2 (en) * | 2005-06-13 | 2006-12-20 | Bioretec Oy | Bioabsorbable implant having a varying characteristic |
EP1862143A1 (en) * | 2006-05-18 | 2007-12-05 | Marcello Marchesi | Method for the guided regeneration of bone and/or periodontal tissues in the medical surgical and dental field and device thus obtainable |
EP1961433A1 (en) * | 2007-02-20 | 2008-08-27 | National University of Ireland Galway | Porous substrates for implantation |
US8563024B2 (en) | 2001-10-16 | 2013-10-22 | Biocomposites Ltd. | Biodegradable material components |
US8876860B2 (en) | 2008-03-14 | 2014-11-04 | Cordis Corporation | Vascular closure device |
CN104146793A (en) * | 2014-07-28 | 2014-11-19 | 浙江大学 | Biological-activity organ manufacturing method |
CN104840272A (en) * | 2015-05-11 | 2015-08-19 | 浙江大学 | Printing method for three-dimensional biological structure with built-in nutrition channel |
WO2015143553A1 (en) | 2014-03-25 | 2015-10-01 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
EP2919823A4 (en) * | 2012-11-14 | 2016-07-13 | Orthopaedic Innovation Ct Inc | Antimicrobial articles produced by additive manufacturing |
CN106232331A (en) * | 2014-04-30 | 2016-12-14 | 惠普发展公司,有限责任合伙企业 | Computer model and three-dimensional (3D) printing process |
CN107887474A (en) * | 2017-11-10 | 2018-04-06 | 艾尔碧全球绿色科技有限公司 | Possess naked colored solar module and manufacture method regarding 3D patterns |
CN109069251A (en) * | 2015-12-04 | 2018-12-21 | 制定实验室公司 | The texturizing surfaces of implantation material |
EP3433084A4 (en) * | 2016-07-20 | 2019-12-18 | Hewlett-Packard Development Company, L.P. | Forming microstructures in 3d printing |
FR3096257A1 (en) * | 2019-05-20 | 2020-11-27 | Vincent HORNEZ | Bone implant and implantation set comprising such a bone implant |
Families Citing this family (223)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524335B2 (en) * | 1997-05-30 | 2009-04-28 | Smith & Nephew, Inc. | Fiber-reinforced, porous, biodegradable implant device |
US8563232B2 (en) | 2000-09-12 | 2013-10-22 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
US6699287B2 (en) * | 1998-09-24 | 2004-03-02 | Korea Atomic Energy Research Institute | Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix |
CA2363262C (en) * | 1999-03-04 | 2010-09-28 | Tepha, Inc. | Bioabsorbable, biocompatible polymers for tissue engineering |
US9616150B2 (en) * | 1999-10-29 | 2017-04-11 | Children's Hospital Los Angeles | Bone hemostasis method and materials |
US7300619B2 (en) | 2000-03-13 | 2007-11-27 | Objet Geometries Ltd. | Compositions and methods for use in three dimensional model printing |
ITVI20000025U1 (en) * | 2000-04-07 | 2001-10-07 | Tecres Spa | TEMPORARY SPACER DEVICE FOR SURGICAL TREATMENT OF THE KNEE |
US6673603B2 (en) * | 2000-09-01 | 2004-01-06 | Modex Therapeutiques, S.A. | Cell paste comprising keratinocytes and fibroblasts |
ES2340141T3 (en) * | 2000-12-28 | 2010-05-31 | Fidia Advanced Biopolymers S.R.L. | USE OF BIOLOGICAL MATERIAL THAT CONTAINS TISSULAR MATRIXS TRISIMENSIONAL SUPPORT OF DERIVATIVES OF THE HIALURONIC ACID FOR THE PREPARATION OF IMPLANTS OF ARTHROSCOPY AND A KIT FOR INSTRUMENTS TO IMPLEMENT SUCH BIOLOGICAL MATERIAL THROUGH ARTHROSCOPY. |
US8123814B2 (en) | 2001-02-23 | 2012-02-28 | Biomet Manufacturing Corp. | Method and appartus for acetabular reconstruction |
US7597715B2 (en) | 2005-04-21 | 2009-10-06 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
WO2002083194A1 (en) * | 2001-04-12 | 2002-10-24 | Therics, Inc. | Method and apparatus for engineered regenerative biostructures |
US20040265385A1 (en) * | 2001-04-12 | 2004-12-30 | Therics, Inc. | Porous biostructure partially occupied by interpenetrant and method for making same |
DE10130968B4 (en) * | 2001-06-27 | 2009-08-20 | Envisiontec Gmbh | Coated polymeric material, its use and process for its preparation |
WO2003039614A1 (en) * | 2001-11-06 | 2003-05-15 | Shin-Ichi Kanemaru | Base material for regenerating air sinus and regeneration method |
US20050209687A1 (en) * | 2002-02-19 | 2005-09-22 | Bioartis, Inc. | Artificial vessel scaffold and artifical organs therefrom |
US20030175410A1 (en) * | 2002-03-18 | 2003-09-18 | Campbell Phil G. | Method and apparatus for preparing biomimetic scaffold |
US8529956B2 (en) * | 2002-03-18 | 2013-09-10 | Carnell Therapeutics Corporation | Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
US8293530B2 (en) * | 2006-10-17 | 2012-10-23 | Carnegie Mellon University | Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
US20100254900A1 (en) * | 2002-03-18 | 2010-10-07 | Campbell Phil G | Biocompatible polymers and Methods of use |
DE60333179D1 (en) * | 2002-03-29 | 2010-08-12 | Osteotech Inc | METHOD FOR PRODUCING BONE PARTICLES |
US7931687B2 (en) * | 2002-05-13 | 2011-04-26 | Articular Engineering, Llc | Tissue engineered osteochondral implant |
US8187326B2 (en) | 2002-05-22 | 2012-05-29 | Advanced Technologies And Regenerative Medicine, Llc. | Attachment of absorbable tissue scaffolds to fixation devices |
JP3916516B2 (en) * | 2002-06-10 | 2007-05-16 | 独立行政法人科学技術振興機構 | Scaffolding material for hard tissue-soft tissue interface regeneration |
US20060147332A1 (en) | 2004-12-30 | 2006-07-06 | Howmedica Osteonics Corp. | Laser-produced porous structure |
CA2448592C (en) | 2002-11-08 | 2011-01-11 | Howmedica Osteonics Corp. | Laser-produced porous surface |
EP1596767B1 (en) * | 2003-02-12 | 2018-10-03 | Syncera, Inc. | Random and non-random alkylene oxide polymer alloy compositions |
US20050008990A1 (en) * | 2003-02-26 | 2005-01-13 | Therics, Inc. | Method and system for repairing endosseous implants, such as with a bone graft implant |
WO2004075940A1 (en) * | 2003-02-26 | 2004-09-10 | Zimmer Orthobiologics, Inc. | Preparation for repairing cartilage tissue, especially articular cartilage defects |
WO2004082524A2 (en) * | 2003-03-13 | 2004-09-30 | William Marsh Rice University | Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material |
US20050007430A1 (en) * | 2003-03-24 | 2005-01-13 | Therics, Inc. | Method and system of printheads using electrically conductive solvents |
US7317964B1 (en) | 2003-04-04 | 2008-01-08 | The United States Of America As Represented By The Secretary Of The Air Force | High speed and repeatability serial sectioning method for 3-D reconstruction of microstructures |
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
DK1638615T3 (en) | 2003-05-08 | 2015-01-12 | Tepha Inc | MEDICAL POLYHYDROXYALKANOATE TEXTILES AND FIBERS |
BRPI0410324A (en) | 2003-05-15 | 2006-05-23 | Biomerix Corp | implantable device, elastomeric matrix production lyophilization processes having a cross-linked structure, polymerization for cross-linked elastomeric matrix preparation and cross-linked composite elastomeric implant preparation, and method for treating an orthopedic disorder |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7051654B2 (en) * | 2003-05-30 | 2006-05-30 | Clemson University | Ink-jet printing of viable cells |
GB0312909D0 (en) * | 2003-06-05 | 2003-07-09 | Univ Liverpool | Apparatus for manufacturing three dimensional items |
WO2005011536A1 (en) * | 2003-07-31 | 2005-02-10 | Riken | Artificial bone forming method by powder lamination method |
US7422713B2 (en) | 2003-10-14 | 2008-09-09 | Hewlett-Packard Development Company, L.P. | Hybrid organic-inorganic composition for solid freeform fabrication |
US20050085922A1 (en) * | 2003-10-17 | 2005-04-21 | Shappley Ben R. | Shaped filler for implantation into a bone void and methods of manufacture and use thereof |
US7455805B2 (en) | 2003-10-28 | 2008-11-25 | Hewlett-Packard Development Company, L.P. | Resin-modified inorganic phosphate cement for solid freeform fabrication |
US20050100578A1 (en) * | 2003-11-06 | 2005-05-12 | Schmid Steven R. | Bone and tissue scaffolding and method for producing same |
CA2545941A1 (en) * | 2003-11-14 | 2005-06-23 | Drexel University | Method and apparatus for computer-aided tissue engineering for modeling, design and freeform fabrication of tissue scaffolds, constructs, and devices |
US7763077B2 (en) * | 2003-12-24 | 2010-07-27 | Biomerix Corporation | Repair of spinal annular defects and annulo-nucleoplasty regeneration |
DE102004003485B4 (en) * | 2004-01-23 | 2005-06-16 | Eos Gmbh Electro Optical Systems | Layer-building method for producing a three-dimensional object and suitable material systems |
WO2005089127A2 (en) * | 2004-03-05 | 2005-09-29 | The Trustees Of Columbia University In The City Of New York | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
WO2005086706A2 (en) * | 2004-03-05 | 2005-09-22 | The Trustees Of Columbia University In The City Of New York | Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone |
EP1757315B1 (en) * | 2004-04-30 | 2013-01-02 | Sunstar Suisse SA | Bone regeneration membrane and implant-attached bone regeneration membrane |
WO2005114322A2 (en) * | 2004-05-12 | 2005-12-01 | Massachusetts Institute Of Technology | Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like |
US20060018942A1 (en) * | 2004-05-28 | 2006-01-26 | Rowe Charles W | Polymeric microbeads having characteristics favorable for bone growth, and process including three dimensional printing upon such microbeads |
WO2006033698A2 (en) * | 2004-07-12 | 2006-03-30 | Isto Technologies, Inc. | Tissue matrix system |
US8512730B2 (en) * | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
EP2221069B1 (en) | 2004-08-03 | 2012-05-09 | Tepha, Inc. | Non-curling polyhydroxyalkanoate sutures |
US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US7837740B2 (en) * | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20060083771A1 (en) * | 2004-10-15 | 2006-04-20 | Gc Corporation | Block-shaped scaffold for tissue engineering and production method thereof |
US20060093646A1 (en) * | 2004-10-28 | 2006-05-04 | Cima Michael J | Orthopedic and dental implant devices providing controlled drug delivery |
CA2587308A1 (en) | 2004-11-12 | 2006-05-18 | Mayo Foundation For Medical Education And Research | Photocrosslinkable poly(caprolactone fumarate) |
US8771294B2 (en) | 2004-11-26 | 2014-07-08 | Biomerix Corporation | Aneurysm treatment devices and methods |
WO2006062518A2 (en) | 2004-12-08 | 2006-06-15 | Interpore Spine Ltd. | Continuous phase composite for musculoskeletal repair |
WO2006083946A2 (en) * | 2005-02-01 | 2006-08-10 | Osteobiologics, Inc. | Method and device for selective addition of a bioactive agent to a multi-phase implant |
US7825083B2 (en) * | 2005-02-10 | 2010-11-02 | Spine Wave, Inc. | Synovial fluid barrier |
US9427496B2 (en) | 2005-02-18 | 2016-08-30 | Drexel University | Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering |
US9168328B2 (en) * | 2005-02-25 | 2015-10-27 | Drexel University | Layered manufacturing utilizing foam as a support and multifunctional material for the creation of parts and for tissue engineering |
GB2424223C (en) * | 2005-03-07 | 2011-02-02 | Massachusetts Inst Technology | Biomaterial. |
US8066778B2 (en) | 2005-04-21 | 2011-11-29 | Biomet Manufacturing Corp. | Porous metal cup with cobalt bearing surface |
US8292967B2 (en) | 2005-04-21 | 2012-10-23 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
US8266780B2 (en) | 2005-04-21 | 2012-09-18 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
US8021432B2 (en) | 2005-12-05 | 2011-09-20 | Biomet Manufacturing Corp. | Apparatus for use of porous implants |
WO2006118987A1 (en) * | 2005-04-29 | 2006-11-09 | Mayo Foundation For Medical Education And Research | Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof |
US8506646B2 (en) * | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
WO2007035778A2 (en) * | 2005-09-19 | 2007-03-29 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
EP1764117A1 (en) * | 2005-09-20 | 2007-03-21 | Zimmer GmbH | Implant for the repair of a cartilage defect and method for manufacturing the implant |
US8728387B2 (en) | 2005-12-06 | 2014-05-20 | Howmedica Osteonics Corp. | Laser-produced porous surface |
US8444968B2 (en) * | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
CA2572095C (en) * | 2005-12-30 | 2009-12-08 | Howmedica Osteonics Corp. | Laser-produced implants |
EP1864687B1 (en) * | 2006-06-09 | 2013-07-31 | Eidgenössische Technische Hochschule Zürich | Scaffolds for artificial heart valves and vascular structures |
DE102006029298B4 (en) * | 2006-06-23 | 2008-11-06 | Stiftung Caesar Center Of Advanced European Studies And Research | Material system for 3D printing, process for its production, granules made from the material system and its use |
US8147861B2 (en) | 2006-08-15 | 2012-04-03 | Howmedica Osteonics Corp. | Antimicrobial implant |
US8529961B2 (en) | 2006-10-17 | 2013-09-10 | Carmell Therapeutics Corporation | Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
GB0623065D0 (en) * | 2006-11-18 | 2006-12-27 | Smith & Nephew | Annular ring |
US7943683B2 (en) | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
US20100047309A1 (en) * | 2006-12-06 | 2010-02-25 | Lu Helen H | Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods |
FR2911773B1 (en) | 2007-01-30 | 2009-03-27 | Tornier Sas | METHOD AND ASSEMBLY OF SURGICAL INSTRUMENTATION FOR POSITIONING A TOTAL REVERSE SHOULDER PROSTHESIS, AND CORRESPONDING PROSTHESIS |
US20090287309A1 (en) | 2007-01-30 | 2009-11-19 | Tornier Sas | Intra-articular joint replacement |
US8753391B2 (en) * | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
WO2008134491A1 (en) * | 2007-04-25 | 2008-11-06 | Northwestern University | A biodegradable vascularizing membrane and methods thereof |
JP5280432B2 (en) * | 2007-04-27 | 2013-09-04 | ヒュンジン ヤン | Cell culture support having increased specific gravity and method for producing the same |
US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
US9421304B2 (en) | 2007-07-03 | 2016-08-23 | Histogenics Corporation | Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US20090024224A1 (en) | 2007-07-16 | 2009-01-22 | Chen Silvia S | Implantation of cartilage |
WO2009014718A1 (en) * | 2007-07-24 | 2009-01-29 | Porex Corporation | Porous laser sintered articles |
US8265949B2 (en) | 2007-09-27 | 2012-09-11 | Depuy Products, Inc. | Customized patient surgical plan |
US9173662B2 (en) | 2007-09-30 | 2015-11-03 | DePuy Synthes Products, Inc. | Customized patient-specific tibial cutting blocks |
WO2011106399A1 (en) | 2010-02-25 | 2011-09-01 | Depuy Products, Inc. | Customized patient-specific bone cutting blocks |
EP2957244B1 (en) * | 2007-09-30 | 2020-04-15 | DePuy Products, Inc. | Method of generating a customized patient-specific orthopaedic surgical instrumentation |
US8357111B2 (en) | 2007-09-30 | 2013-01-22 | Depuy Products, Inc. | Method and system for designing patient-specific orthopaedic surgical instruments |
WO2011106400A1 (en) | 2010-02-25 | 2011-09-01 | Depuy Products, Inc. | Customized patient-specific tibial cutting blocks |
US9597837B1 (en) * | 2007-11-15 | 2017-03-21 | Robocasting Enterprises, LLC | Method for making a fluidic device |
CA2717725A1 (en) | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
WO2009116950A1 (en) * | 2008-03-17 | 2009-09-24 | Nanyang Polytechnic | Mould for casting tissue engineering scaffolds and process for generating the same |
GB0809721D0 (en) * | 2008-05-28 | 2008-07-02 | Univ Bath | Improvements in or relating to joints and/or implants |
US20100042213A1 (en) | 2008-08-13 | 2010-02-18 | Nebosky Paul S | Drug delivery implants |
US10842645B2 (en) | 2008-08-13 | 2020-11-24 | Smed-Ta/Td, Llc | Orthopaedic implant with porous structural member |
US9616205B2 (en) | 2008-08-13 | 2017-04-11 | Smed-Ta/Td, Llc | Drug delivery implants |
US9700431B2 (en) | 2008-08-13 | 2017-07-11 | Smed-Ta/Td, Llc | Orthopaedic implant with porous structural member |
WO2010019788A1 (en) | 2008-08-13 | 2010-02-18 | Smed-Ta/Td. Llc | Drug delivery implants |
US10010500B2 (en) * | 2008-08-21 | 2018-07-03 | Biomet Manufacturing, Llc | Ceramic implants affording controlled release of active materials |
WO2010025386A1 (en) | 2008-08-29 | 2010-03-04 | Smed-Ta/Td, Llc | Orthopaedic implant |
US8545856B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8788211B2 (en) | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
US8485861B2 (en) | 2008-10-31 | 2013-07-16 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US8798932B2 (en) | 2008-10-31 | 2014-08-05 | The Invention Science Fund I, Llc | Frozen compositions and methods for piercing a substrate |
US8221480B2 (en) * | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US8475531B1 (en) | 2009-04-21 | 2013-07-02 | Scott A. Maxson | Anchored multi-phasic osteochondral construct |
EP2456473B1 (en) * | 2009-07-23 | 2016-02-17 | Didier Nimal | Biomedical device, method for manufacturing the same and use thereof |
US9889012B2 (en) | 2009-07-23 | 2018-02-13 | Didier NIMAL | Biomedical device, method for manufacturing the same and use thereof |
US9399086B2 (en) * | 2009-07-24 | 2016-07-26 | Warsaw Orthopedic, Inc | Implantable medical devices |
CN102573704B (en) | 2009-08-19 | 2016-03-16 | 史密夫和内修有限公司 | Porous implant structures |
US20110177590A1 (en) * | 2009-12-11 | 2011-07-21 | Drexel University | Bioprinted Nanoparticles and Methods of Use |
CN102695476B (en) * | 2009-12-30 | 2015-06-17 | 斯恩蒂斯有限公司 | Implant |
US8444699B2 (en) * | 2010-02-18 | 2013-05-21 | Biomet Manufacturing Corp. | Method and apparatus for augmenting bone defects |
WO2011106407A1 (en) | 2010-02-25 | 2011-09-01 | Depuy Products, Inc. | Method of fabricating customized patient-specific bone cutting blocks |
ES2704658T3 (en) | 2010-02-25 | 2019-03-19 | Depuy Products Inc | Custom patient-specific bone cutting blocks |
IT1398443B1 (en) * | 2010-02-26 | 2013-02-22 | Lima Lto S P A Ora Limacorporate Spa | INTEGRATED PROSTHETIC ELEMENT |
US9408652B2 (en) | 2010-04-27 | 2016-08-09 | Tornier Sas | Intra-articular joint replacement and method |
US8727203B2 (en) | 2010-09-16 | 2014-05-20 | Howmedica Osteonics Corp. | Methods for manufacturing porous orthopaedic implants |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
GB2485848B (en) | 2010-11-29 | 2018-07-11 | Halliburton Energy Services Inc | Improvements in heat flow control for molding downhole equipment |
GB2490087B (en) * | 2010-11-29 | 2016-04-27 | Halliburton Energy Services Inc | Forming objects by infiltrating a printed matrix |
GB201108185D0 (en) * | 2011-05-17 | 2011-06-29 | Depuy Spine Sarl | Medical implant, method for manufacturing a medical implant and curable mixture |
US8641721B2 (en) | 2011-06-30 | 2014-02-04 | DePuy Synthes Products, LLC | Customized patient-specific orthopaedic pin guides |
AU2012286817A1 (en) | 2011-07-26 | 2014-02-13 | The Curators Of The University Of Missouri | Engineered comestible meat |
FR2979817B1 (en) * | 2011-09-13 | 2014-08-01 | Jean-Michel Bertin | PROCESS FOR PRODUCING PROSTHESIS BY RAPID PROTOTYPING |
JP6018477B2 (en) * | 2011-11-11 | 2016-11-02 | Hoya株式会社 | Artificial bone-cartilage complex and method for producing the same |
US8414654B1 (en) * | 2011-11-23 | 2013-04-09 | Amendia, Inc. | Bone implants and method of manufacture |
US9642935B1 (en) * | 2012-01-27 | 2017-05-09 | Robert L. Bundy | Synthetic, composite osteogenic bone graft |
US9364896B2 (en) | 2012-02-07 | 2016-06-14 | Medical Modeling Inc. | Fabrication of hybrid solid-porous medical implantable devices with electron beam melting technology |
JP5890222B2 (en) * | 2012-03-30 | 2016-03-22 | 株式会社ジーシー | Cultured cartilage tissue material |
US9180010B2 (en) | 2012-04-06 | 2015-11-10 | Howmedica Osteonics Corp. | Surface modified unit cell lattice structures for optimized secure freeform fabrication |
US9135374B2 (en) | 2012-04-06 | 2015-09-15 | Howmedica Osteonics Corp. | Surface modified unit cell lattice structures for optimized secure freeform fabrication |
JP2015517879A (en) * | 2012-05-30 | 2015-06-25 | ニューヨーク ユニバーシティ | Tissue repair device or scaffold |
US8843229B2 (en) * | 2012-07-20 | 2014-09-23 | Biomet Manufacturing, Llc | Metallic structures having porous regions from imaged bone at pre-defined anatomic locations |
US10172651B2 (en) | 2012-10-25 | 2019-01-08 | Warsaw Orthopedic, Inc. | Cortical bone implant |
US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
WO2014089711A1 (en) * | 2012-12-11 | 2014-06-19 | Dr.H.C. Robert Mathys Stiftung | Bone substitute and method for producing same |
US9265609B2 (en) | 2013-01-08 | 2016-02-23 | Warsaw Orthopedic, Inc. | Osteograft implant |
WO2014144488A1 (en) * | 2013-03-15 | 2014-09-18 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | 3d biomimetic, bi-phasic key featured scaffold for osteochondral repair |
WO2014169249A1 (en) | 2013-04-12 | 2014-10-16 | The Trustees Of Columbia University In The City Of New York | Methods for host cell homing and dental pulp regeneration |
US10471497B2 (en) | 2013-08-16 | 2019-11-12 | The Exone Company | Three-dimensional printed metal-casting molds and methods for making the same |
WO2015038988A1 (en) | 2013-09-13 | 2015-03-19 | Modern Meadow, Inc. | Edible and animal-product-free microcarriers for engineered meat |
US20160243621A1 (en) | 2013-10-17 | 2016-08-25 | The Exone Company | Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US20160332373A1 (en) | 2013-12-23 | 2016-11-17 | The Exone Company | Methods and Systems for Three-Dimensional Printing Utilizing Multiple Binder Fluids |
EP3086922B1 (en) | 2013-12-23 | 2022-03-09 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
CA2938156C (en) | 2014-02-05 | 2022-05-10 | Modern Meadow, Inc. | Dried food products formed from cultured muscle cells |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
EP3148730A1 (en) | 2014-05-29 | 2017-04-05 | The Exone Company | Process for making nickel-based superalloy articles by three-dimensional printing |
US9670443B2 (en) * | 2014-06-25 | 2017-06-06 | University Of Leeds | Tissue engineered constructs |
WO2016011098A2 (en) | 2014-07-17 | 2016-01-21 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
US10500303B2 (en) | 2014-08-15 | 2019-12-10 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
KR101506704B1 (en) | 2014-09-02 | 2015-03-27 | 조선대학교산학협력단 | Porous scaffold based on high density poly ethylene using 3D printing and manufacturing method thereof |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
WO2016089618A1 (en) | 2014-12-03 | 2016-06-09 | The Exone Company | Process for making densified carbon articles by three dimensional printing |
KR102380005B1 (en) * | 2014-12-09 | 2022-03-29 | 고려대학교 산학협력단 | Osteoinductive Molecules-eluting Scaffold and Method for Preparing thereof |
EP3230500A1 (en) | 2014-12-11 | 2017-10-18 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
US10238507B2 (en) | 2015-01-12 | 2019-03-26 | Surgentec, Llc | Bone graft delivery system and method for using same |
EP3050540B1 (en) | 2015-01-27 | 2022-04-20 | K2M, Inc. | Spinal implant |
US10028841B2 (en) | 2015-01-27 | 2018-07-24 | K2M, Inc. | Interbody spacer |
RU2597786C2 (en) * | 2015-02-10 | 2016-09-20 | Общество с ограниченной ответственностью "НекстГен" | Method for creating personalized gene-activated implant for bone tissue regeneration |
US11434766B2 (en) * | 2015-03-05 | 2022-09-06 | General Electric Company | Process for producing a near net shape component with consolidation of a metallic powder |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US10470887B2 (en) * | 2015-08-27 | 2019-11-12 | Institute of Orthopedic Research & Education | Modification of the surface topography of cartilage grafts for joint reconstruction |
US10059092B2 (en) | 2015-09-14 | 2018-08-28 | Baker Hughes, A Ge Company, Llc | Additive manufacturing of functionally gradient degradable tools |
US10335855B2 (en) * | 2015-09-14 | 2019-07-02 | Baker Hughes, A Ge Company, Llc | Additive manufacturing of functionally gradient degradable tools |
ES2842501T5 (en) | 2015-09-21 | 2023-04-13 | Modern Meadow Inc | Fiber Reinforced Fabric Composite Materials |
EP3359088A4 (en) * | 2015-10-05 | 2020-03-04 | Formae Inc. | Medical implant and anchoring system for a medical implant |
EP3359594A4 (en) * | 2015-10-09 | 2019-07-03 | Hewlett-Packard Development Company, L.P. | Particulate mixtures |
EP3361999A4 (en) * | 2015-10-13 | 2019-06-26 | K2M, Inc. | Interbody spacer |
KR20170096093A (en) | 2016-02-15 | 2017-08-23 | 브렌던 패트릭 퍼셀 | Composite biofabricated material |
WO2017192525A1 (en) * | 2016-05-02 | 2017-11-09 | Marquette University | Reinforced bone scaffold |
US10889057B2 (en) | 2016-05-12 | 2021-01-12 | Hewlett-Packard Development Company, L.P. | Material sets |
WO2017201371A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomimetic plywood motifs for bone tissue engineering |
US11638645B2 (en) * | 2016-05-19 | 2023-05-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomimetic plywood motifs for bone tissue engineering |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
CN109311224B (en) * | 2016-06-08 | 2020-12-29 | 富士胶片株式会社 | Method for producing gelatin molded body and gelatin molded body |
US10287548B2 (en) | 2016-06-29 | 2019-05-14 | General Electric Company | Method and device for closed system culture of cartilage tissue |
US10022231B2 (en) * | 2016-07-22 | 2018-07-17 | Cytex Therapeutics, Inc. | Articular cartilage repair |
US20190203038A1 (en) * | 2016-08-03 | 2019-07-04 | Wake Forest University Health Sciences | Composition with polymer and ceramic and methods of use thereof |
JP2019532176A (en) * | 2016-09-09 | 2019-11-07 | アーコニック インコーポレイテッドArconic Inc. | Aluminum alloy product and manufacturing method thereof |
US10150282B2 (en) | 2016-10-14 | 2018-12-11 | Xerox Corporation | System and method for additive manufacture of chemical delivery devices using halftone screening |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11298747B2 (en) | 2017-05-18 | 2022-04-12 | Howmedica Osteonics Corp. | High fatigue strength porous structure |
KR102645701B1 (en) * | 2017-09-03 | 2024-03-12 | 에보니크 오퍼레이션즈 게엠베하 | Biocompatible polymer powders for additive manufacturing |
CN111511900B (en) | 2017-11-09 | 2021-12-31 | 南加利福尼亚大学阿尔弗雷德·E·曼恩生物医学工程研究所 | Stem cells and devices for bone regeneration |
AU2018253595A1 (en) | 2017-11-13 | 2019-05-30 | Modern Meadow, Inc. | Biofabricated leather articles having zonal properties |
US10687828B2 (en) | 2018-04-13 | 2020-06-23 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11116647B2 (en) | 2018-04-13 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11051829B2 (en) | 2018-06-26 | 2021-07-06 | DePuy Synthes Products, Inc. | Customized patient-specific orthopaedic surgical instrument |
US11426818B2 (en) | 2018-08-10 | 2022-08-30 | The Research Foundation for the State University | Additive manufacturing processes and additively manufactured products |
EP3704202A4 (en) | 2019-01-17 | 2020-12-16 | Modern Meadow, Inc. | Layered collagen materials and methods of making the same |
CN109809810A (en) * | 2019-03-07 | 2019-05-28 | 华南理工大学 | A kind of bioactive ceramics bracket and preparation method thereof with heterogeneous porous bionical natural bony structure |
DE202019106375U1 (en) * | 2019-11-15 | 2019-11-25 | Kumovis GmbH | Orthopedic implant |
CA3197747A1 (en) * | 2020-10-06 | 2022-04-14 | Tensive Srl | Three-dimensional implantable matrix with reduced foreign body response |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
WO1995011007A1 (en) * | 1993-10-18 | 1995-04-27 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
WO1996040002A1 (en) * | 1995-06-07 | 1996-12-19 | Massachusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free-form fabrication methods |
US5607474A (en) | 1992-02-14 | 1997-03-04 | Board Of Regents, University Of Texas System | Multi-phase bioerodible implant/carrier and method of manufacturing and using same |
US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
WO1998036739A1 (en) * | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof |
WO1998041189A1 (en) * | 1997-03-20 | 1998-09-24 | Therics, Inc. | Fabrication of tissue products using a mold formed by solid free-form methods |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4787900A (en) | 1982-04-19 | 1988-11-29 | Massachusetts Institute Of Technology | Process for forming multilayer bioreplaceable blood vessel prosthesis |
US4520821A (en) | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
US4485097A (en) | 1982-05-26 | 1984-11-27 | Massachusetts Institute Of Technology | Bone-equivalent and method for preparation thereof |
JPS6021763A (en) | 1983-07-15 | 1985-02-04 | ティーディーケイ株式会社 | Artificial bone material |
US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
US4620327A (en) | 1984-07-05 | 1986-11-04 | Caplan Arnold I | Process of adapting soluble bone protein for use in stimulating osteoinduction |
DE3684446D1 (en) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | MEDICINAL PRODUCTS WITH DELAYED RELEASED RELEASE. |
US4927632A (en) | 1986-06-26 | 1990-05-22 | Alza Corporation | Selective pulsed drug delivery system |
US5108926A (en) | 1987-09-08 | 1992-04-28 | Board Of Regents, The University Of Texas System | Apparatus for the precise positioning of cells |
NL8801741A (en) | 1988-07-08 | 1990-02-01 | Utermoehlen Nv | ART SKIN. |
JP2678945B2 (en) | 1989-04-17 | 1997-11-19 | 有限会社ナイセム | Artificial blood vessel, method for producing the same, and substrate for artificial blood vessel |
US5387380A (en) | 1989-12-08 | 1995-02-07 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US5204055A (en) * | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US5059123A (en) | 1990-05-14 | 1991-10-22 | Jernberg Gary R | Periodontal barrier and method for aiding periodontal tissue regeneration |
AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5197985A (en) | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5226914A (en) | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5460758A (en) * | 1990-12-21 | 1995-10-24 | Eos Gmbh Electro Optical Systems | Method and apparatus for production of a three-dimensional object |
DE4102259A1 (en) | 1991-01-23 | 1992-07-30 | Artos Med Produkte | Prodn. of shapes e.g. artificial bones - by using computer-controlled laser beam to cure suitable liq. in successive layers corresp. to contours of scanned master article |
US5348788A (en) | 1991-01-30 | 1994-09-20 | Interpore Orthopaedics, Inc. | Mesh sheet with microscopic projections and holes |
ATE131111T1 (en) | 1991-01-31 | 1995-12-15 | Texas Instruments Inc | METHOD AND DEVICE FOR THE COMPUTER-CONTROLLED PRODUCTION OF THREE-DIMENSIONAL OBJECTS FROM COMPUTER DATA. |
DE4120325A1 (en) | 1991-06-20 | 1992-12-24 | Merck Patent Gmbh | IMPLANT MATERIAL |
US5681572A (en) | 1991-10-18 | 1997-10-28 | Seare, Jr.; William J. | Porous material product and process |
WO1993008850A1 (en) | 1991-10-30 | 1993-05-13 | Massachusetts Institute Of Technology | Prevascularized polymeric implants for organ transplantation |
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
GB9206509D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges containing active agents |
US5496372A (en) | 1992-04-17 | 1996-03-05 | Kyocera Corporation | Hard tissue prosthesis including porous thin metal sheets |
US5510066A (en) | 1992-08-14 | 1996-04-23 | Guild Associates, Inc. | Method for free-formation of a free-standing, three-dimensional body |
US5370692A (en) | 1992-08-14 | 1994-12-06 | Guild Associates, Inc. | Rapid, customized bone prosthesis |
US5518680A (en) | 1993-10-18 | 1996-05-21 | Massachusetts Institute Of Technology | Tissue regeneration matrices by solid free form fabrication techniques |
US6270335B2 (en) * | 1995-09-27 | 2001-08-07 | 3D Systems, Inc. | Selective deposition modeling method and apparatus for forming three-dimensional objects and supports |
DE69903800T2 (en) * | 1998-03-18 | 2003-10-02 | Massachusetts Inst Technology | VASCULARIZED PERFUNDED ARRANGEMENTS FOR MICRO TISSUE AND MICROORGANES |
US6224630B1 (en) * | 1998-05-29 | 2001-05-01 | Advanced Bio Surfaces, Inc. | Implantable tissue repair device |
-
1999
- 1999-10-12 US US09/416,346 patent/US6454811B1/en not_active Expired - Lifetime
- 1999-10-12 AU AU64271/99A patent/AU768641B2/en not_active Ceased
- 1999-10-12 EP EP99951941A patent/EP1121072A1/en not_active Withdrawn
- 1999-10-12 CA CA002345982A patent/CA2345982A1/en not_active Abandoned
- 1999-10-12 JP JP2000575451A patent/JP2002527144A/en not_active Withdrawn
- 1999-10-12 WO PCT/US1999/023732 patent/WO2000021470A1/en not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5607474A (en) | 1992-02-14 | 1997-03-04 | Board Of Regents, University Of Texas System | Multi-phase bioerodible implant/carrier and method of manufacturing and using same |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
WO1995011007A1 (en) * | 1993-10-18 | 1995-04-27 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5626861A (en) | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
WO1996040002A1 (en) * | 1995-06-07 | 1996-12-19 | Massachusetts Institute Of Technology | Vascularized tissue regeneration matrices formed by solid free-form fabrication methods |
WO1998036739A1 (en) * | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage forms exhibiting multiphasic release kinetics and methods of manufacture thereof |
WO1998041189A1 (en) * | 1997-03-20 | 1998-09-24 | Therics, Inc. | Fabrication of tissue products using a mold formed by solid free-form methods |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU782297B2 (en) * | 1999-06-30 | 2005-07-14 | Ethicon Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
JP2001049018A (en) * | 1999-06-30 | 2001-02-20 | Ethicon Inc | Porous tissue skeleton forming material for repair and regeneration of tissue |
US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
EP1064958A1 (en) * | 1999-06-30 | 2001-01-03 | Ethicon, Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
US7112417B2 (en) | 1999-06-30 | 2006-09-26 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
EP1452191A2 (en) * | 1999-06-30 | 2004-09-01 | Ethicon, Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
EP1452191A3 (en) * | 1999-06-30 | 2004-09-22 | Ethicon, Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
EP1234587A1 (en) * | 2001-02-26 | 2002-08-28 | Ethicon, Inc. | Biocompatible foam composite |
FR2828408A1 (en) * | 2001-08-09 | 2003-02-14 | Asahi Optical Co Ltd | Implant forming method e.g. artificial skull bone involves forming layer of ingredient powder, applying reactant liquid to layer to harden specific portions |
JP2003052804A (en) * | 2001-08-09 | 2003-02-25 | Ichiro Ono | Manufacturing method for implant and implant |
US8563024B2 (en) | 2001-10-16 | 2013-10-22 | Biocomposites Ltd. | Biodegradable material components |
US7931914B2 (en) | 2001-10-29 | 2011-04-26 | Massachusetts Institute Of Technology | System and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form |
WO2003037607A1 (en) * | 2001-10-29 | 2003-05-08 | Therics, Inc. | A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form |
WO2003045460A1 (en) * | 2001-11-27 | 2003-06-05 | Takiron Co., Ltd. | Implant material and process for producing the same |
US8119152B2 (en) | 2001-11-27 | 2012-02-21 | Takiron Co., Ltd. | Implant material and process for producing the same |
EP1366718A3 (en) * | 2002-05-31 | 2006-04-19 | Ethicon, Inc. | Attachment of absorbable tissue scaffolds to fixation devices |
WO2004010907A1 (en) * | 2002-07-29 | 2004-02-05 | Therics, Inc. | A complex three-dimensional composite scaffold resistant to delamination |
EP1642599A1 (en) * | 2003-05-26 | 2006-04-05 | PENTAX Corporation | Porous composite containing calcium phosphate and process for producing the same |
EP1642599A4 (en) * | 2003-05-26 | 2008-02-13 | Pentax Corp | Porous composite containing calcium phosphate and process for producing the same |
US8039090B2 (en) | 2003-05-26 | 2011-10-18 | Hoya Corporation | Porous composite containing calcium phosphate and process for producing the same |
EP1733746A3 (en) * | 2005-06-13 | 2007-10-17 | Bioretec Oy | Bioabsorbable implant having a varying characteristic |
EP1733746A2 (en) * | 2005-06-13 | 2006-12-20 | Bioretec Oy | Bioabsorbable implant having a varying characteristic |
EP1862143A1 (en) * | 2006-05-18 | 2007-12-05 | Marcello Marchesi | Method for the guided regeneration of bone and/or periodontal tissues in the medical surgical and dental field and device thus obtainable |
EP1961433A1 (en) * | 2007-02-20 | 2008-08-27 | National University of Ireland Galway | Porous substrates for implantation |
US8876860B2 (en) | 2008-03-14 | 2014-11-04 | Cordis Corporation | Vascular closure device |
EP2254482B1 (en) * | 2008-03-14 | 2017-12-06 | Cardinal Health Switzerland 515 GmbH | Vascular closure device |
EP2919823A4 (en) * | 2012-11-14 | 2016-07-13 | Orthopaedic Innovation Ct Inc | Antimicrobial articles produced by additive manufacturing |
US10905740B2 (en) | 2012-11-14 | 2021-02-02 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
AU2015234581B2 (en) * | 2014-03-25 | 2018-06-21 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
WO2015143553A1 (en) | 2014-03-25 | 2015-10-01 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
US10406263B2 (en) | 2014-03-25 | 2019-09-10 | Orthopaedic Innovation Centre Inc. | Antimicrobial articles produced by additive manufacturing |
CN106232331A (en) * | 2014-04-30 | 2016-12-14 | 惠普发展公司,有限责任合伙企业 | Computer model and three-dimensional (3D) printing process |
US10471698B2 (en) | 2014-04-30 | 2019-11-12 | Hewlett-Packard Development Company, L.P. | Computational model and three-dimensional (3D) printing methods |
CN104146793B (en) * | 2014-07-28 | 2015-12-30 | 浙江大学 | A kind of manufacture method with biological activity organ |
CN104146793A (en) * | 2014-07-28 | 2014-11-19 | 浙江大学 | Biological-activity organ manufacturing method |
CN104840272A (en) * | 2015-05-11 | 2015-08-19 | 浙江大学 | Printing method for three-dimensional biological structure with built-in nutrition channel |
CN109069251A (en) * | 2015-12-04 | 2018-12-21 | 制定实验室公司 | The texturizing surfaces of implantation material |
US11202698B2 (en) | 2015-12-04 | 2021-12-21 | Establishment Labs S.A. | Textured surfaces for implants |
US11077612B2 (en) | 2016-07-20 | 2021-08-03 | Hewlett-Packard Development Company, L.P. | Forming microstructures in 3D printing by fusing and sintering using a fusing agent |
EP3433084A4 (en) * | 2016-07-20 | 2019-12-18 | Hewlett-Packard Development Company, L.P. | Forming microstructures in 3d printing |
CN107887474A (en) * | 2017-11-10 | 2018-04-06 | 艾尔碧全球绿色科技有限公司 | Possess naked colored solar module and manufacture method regarding 3D patterns |
FR3096257A1 (en) * | 2019-05-20 | 2020-11-27 | Vincent HORNEZ | Bone implant and implantation set comprising such a bone implant |
Also Published As
Publication number | Publication date |
---|---|
CA2345982A1 (en) | 2000-04-20 |
JP2002527144A (en) | 2002-08-27 |
AU768641B2 (en) | 2003-12-18 |
EP1121072A1 (en) | 2001-08-08 |
US6454811B1 (en) | 2002-09-24 |
AU6427199A (en) | 2000-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6454811B1 (en) | Composites for tissue regeneration and methods of manufacture thereof | |
US20030114936A1 (en) | Complex three-dimensional composite scaffold resistant to delimination | |
Turnbull et al. | 3D bioactive composite scaffolds for bone tissue engineering | |
Babaie et al. | Fabrication aspects of porous biomaterials in orthopedic applications: A review | |
Karageorgiou et al. | Porosity of 3D biomaterial scaffolds and osteogenesis | |
US5518680A (en) | Tissue regeneration matrices by solid free form fabrication techniques | |
Hutmacher | Scaffold design and fabrication technologies for engineering tissues—state of the art and future perspectives | |
US6423252B1 (en) | Methods of making micropatterned foams | |
US6530958B1 (en) | Tissue regeneration matrices by solid free-form fabrication techniques | |
KR100955410B1 (en) | Implant material and process for producing the same | |
Thavornyutikarn et al. | Bone tissue engineering scaffolding: computer-aided scaffolding techniques | |
Liu et al. | Polymeric scaffolds for bone tissue engineering | |
JP3583142B2 (en) | Vascularized tissue regeneration matrix formed by a solid-free fabrication method | |
CN1280508A (en) | Bone substitutes | |
JONES | Scaffolds for tissue engineering | |
Liu et al. | Bioinspired nanocomposites for orthopedic applications | |
Karande et al. | Function and requirement of synthetic scaffolds in tissue engineering | |
Balla et al. | Biointegration of three-dimensional–printed biomaterials and biomedical devices | |
Webster | Nanotechnology for the regeneration of hard and soft tissues | |
Kannan et al. | Synthetic polymeric biomaterials for tissue engineering | |
Wei et al. | Polymeric biomaterials for tissue engineering | |
Woesz | Rapid prototyping to produce porous scaffolds with controlled architecture for possible use in bone tissue engineering | |
Salehi et al. | Three‐dimensional Printing Approaches for the Treatment of Critical‐sized Bone Defects | |
CA2338440C (en) | Foam composite for the repair or regeneration of tissue | |
Ashok et al. | 3D PRINTING OF HYDROXYAPATITE BASED COMPOSITES FOR BONE ENGINEERING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 64271 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2345982 Country of ref document: CA Ref country code: CA Ref document number: 2345982 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 64271/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 575451 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951941 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951941 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 64271/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951941 Country of ref document: EP |